Tillkännagivande • Mar 13
GL Pharm Tech Corp., Annual General Meeting, Mar 26, 2026 GL Pharm Tech Corp., Annual General Meeting, Mar 26, 2026, at 09:01 Tokyo Standard Time. Location: conference room, 257, saemaeul-ro, bundang-gu, gyeonggi-do, seongnam South Korea Reported Earnings • Nov 12
Third quarter 2025 earnings released: EPS: ₩2.00 (vs ₩2.00 loss in 3Q 2024) Third quarter 2025 results: EPS: ₩2.00 (up from ₩2.00 loss in 3Q 2024). Revenue: ₩9.53b (up 104% from 3Q 2024). Net income: ₩132.8m (up ₩250.4m from 3Q 2024). Profit margin: 1.4% (up from net loss in 3Q 2024). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 9% per year but the company’s share price has increased by 16% per year, which means it is tracking significantly ahead of earnings growth. New Risk • Aug 27
New major risk - Financial position The company's interest payments are not well covered by earnings. Net interest cover: 1.1x This is considered a major risk. If the company is unable to fund interest repayments on its debt through profits, it may be forced into reducing its debt burden through selling assets, undertaking a potentially costly capital raising or even into bankruptcy in the worst case scenario. Currently, the following risks have been identified for the company: Major Risk Interest payments are not well covered by earnings (1.1x net interest cover). Minor Risk Market cap is less than US$100m (₩90.2b market cap, or US$64.7m). Reported Earnings • May 16
First quarter 2025 earnings released First quarter 2025 results: Revenue: ₩7.84b (up 34% from 1Q 2024). Net income: ₩24.1m (up ₩1.66b from 1Q 2024). Profit margin: 0.3% (up from net loss in 1Q 2024). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 8% per year but the company’s share price has increased by 7% per year, which means it is well ahead of earnings. New Risk • Apr 23
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 9.1% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Less than 1 year of cash runway based on free cash flow trend (-₩5.0b free cash flow). Minor Risks Share price has been volatile over the past 3 months (9.1% average weekly change). Market cap is less than US$100m (₩109.2b market cap, or US$76.8m). Reported Earnings • Mar 22
Full year 2024 earnings released: ₩31.00 loss per share (vs ₩60.00 loss in FY 2023) Full year 2024 results: ₩31.00 loss per share (improved from ₩60.00 loss in FY 2023). Revenue: ₩26.0b (flat on FY 2023). Net loss: ₩2.34b (loss narrowed 38% from FY 2023). Over the last 3 years on average, earnings per share has increased by 3% per year whereas the company’s share price has increased by 4% per year. Tillkännagivande • Mar 13
GL Pharm Tech Corp., Annual General Meeting, Mar 26, 2025 GL Pharm Tech Corp., Annual General Meeting, Mar 26, 2025, at 09:01 Tokyo Standard Time. Location: conference room, 257, saemaeul-ro, bundang-gu, gyeonggi-do, seongnam South Korea New Risk • Aug 23
New major risk - Financial position The company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -₩4.8b This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risk Less than 1 year of cash runway based on free cash flow trend (-₩4.8b free cash flow). Minor Risks Shareholders have been diluted in the past year (23% increase in shares outstanding). Market cap is less than US$100m (₩80.8b market cap, or US$60.4m). New Risk • Apr 26
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 8.6% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (8.6% average weekly change). Shareholders have been diluted in the past year (24% increase in shares outstanding). Market cap is less than US$100m (₩101.2b market cap, or US$73.6m). New Risk • Mar 30
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 24% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Minor Risks Shareholders have been diluted in the past year (24% increase in shares outstanding). Market cap is less than US$100m (₩104.5b market cap, or US$77.7m). Reported Earnings • Mar 21
Full year 2023 earnings released: ₩60.00 loss per share (vs ₩13.00 loss in FY 2022) Full year 2023 results: ₩60.00 loss per share (further deteriorated from ₩13.00 loss in FY 2022). Revenue: ₩26.0b (up 56% from FY 2022). Net loss: ₩3.75b (loss widened 374% from FY 2022). Over the last 3 years on average, earnings per share has increased by 38% per year but the company’s share price has only increased by 4% per year, which means it is significantly lagging earnings growth. Tillkännagivande • Mar 07
W Science Co., Ltd. completed the acquisition of 14.75% stake in GL Pharm Tech Corp. (KOSDAQ:A204840) from Ideal Private Equity Fund W Science Co., Ltd. agreed to acquire a 14.75% stake in GL Pharm Tech Corp. (KOSDAQ:A204840) from Ideal Private Equity Fund for KRW 15.77 billion on September 14, 2023. W Science Co., Ltd. entered into an agreement to acquire 14.75% stake in GL Pharm Tech Corp. (KOSDAQ:A204840) from Ideal Private Equity Fund, KAIS Inc and Hoon-sik Wang for KRW 15.77 billion on February 28, 2024. The offer per share is KRW 1700 per share. The scheduled transaction closing date is April 29, 2024.
W Science Co., Ltd. completed the acquisition of 14.75% stake in GL Pharm Tech Corp. (KOSDAQ:A204840) from Ideal Private Equity Fund on March 6, 2024. Tillkännagivande • Mar 06
GL Pharm Tech Corp. announced that it has received KRW 9.199999458 billion in funding from W Science Co., Ltd. On March 6, 2024, GL Pharm Tech Corp. closed the transaction. Reported Earnings • Nov 15
Third quarter 2023 earnings released: ₩15.00 loss per share (vs ₩5.00 loss in 3Q 2022) Third quarter 2023 results: ₩15.00 loss per share (further deteriorated from ₩5.00 loss in 3Q 2022). Revenue: ₩7.69b (up 64% from 3Q 2022). Net loss: ₩963.6m (loss widened 280% from 3Q 2022). Over the last 3 years on average, earnings per share has increased by 49% per year but the company’s share price has only increased by 13% per year, which means it is significantly lagging earnings growth. New Risk • Nov 15
New major risk - Financial position The company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -₩3.1b This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₩3.1b free cash flow). Share price has been highly volatile over the past 3 months (14% average weekly change). Minor Risk Market cap is less than US$100m (₩78.1b market cap, or US$59.9m). New Risk • Jul 22
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of South Korean stocks, typically moving 13% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (currently running at an operating cash loss). Share price has been highly volatile over the past 3 months (13% average weekly change). Minor Risks Large one-off items impacting financial results. Market cap is less than US$100m (₩67.7b market cap, or US$52.6m). Reported Earnings • May 14
First quarter 2023 earnings released: ₩10.00 loss per share (vs ₩42.00 loss in 1Q 2022) First quarter 2023 results: ₩10.00 loss per share (improved from ₩42.00 loss in 1Q 2022). Revenue: ₩5.11b (up 103% from 1Q 2022). Net loss: ₩598.2m (loss narrowed 73% from 1Q 2022). Over the last 3 years on average, earnings per share has increased by 59% per year but the company’s share price has fallen by 2% per year, which means it is significantly lagging earnings. Reported Earnings • Nov 08
Third quarter 2022 earnings released: ₩5.00 loss per share (vs ₩5.00 loss in 3Q 2021) Third quarter 2022 results: ₩5.00 loss per share (in line with 3Q 2021). Revenue: ₩4.70b (up 88% from 3Q 2021). Net loss: ₩306.2m (loss narrowed 78% from 3Q 2021). Over the last 3 years on average, earnings per share has increased by 14% per year but the company’s share price has fallen by 17% per year, which means it is significantly lagging earnings. Is New 90 Day High Low • Dec 02
New 90-day high: ₩1,190 The company is up 17% from its price of ₩1,015 on 03 September 2020. The South Korean market is up 10.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is up 1.0% over the same period. Tillkännagivande • Nov 25
GL Pharm Tech Corp. announced that it expects to receive KRW 4.5 billion in funding from Ideal Priavate Equity 1 Co., Ltd. GL Pharm Tech Corp. (KOSDAQ:A204840) announced a private placement of series 6 non-guaranteed private equity convertible bonds with registered interest for gross proceeds of KRW 4,500,000,000 on November 23, 2020. The transaction will include participation from Ideal Priavate Equity 1 Co., Ltd. The bonds will have interest rate of 4% and surface to interest rate 2% and will mature on November 29, 2025. The bonds to be issued are 100% convertible into 4,950,495 shares at a price of KRW 909 for 10.49% equity during the period November 30, 2021 to November 29, 2025. The subscription date is November 23, 2020 and payment date is November 30, 2020. The security to be issued in the transaction will be subject to hold period of one year. The transaction has been approved by the board of directors of the company. Is New 90 Day High Low • Oct 30
New 90-day low: ₩875 The company is down 14% from its price of ₩1,020 on 31 July 2020. The South Korean market is up 3.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 1.0% over the same period. Tillkännagivande • Sep 30
GL Pharm Tech Corp. announced that it has received KRW 1.000000232 billion in funding from Kyperion Co., Ltd. On September 29, 2020, GL Pharm Tech Corp. (KOSDAQ:A204840) closed the transaction. Is New 90 Day High Low • Sep 24
New 90-day low: ₩896 The company is down 10.0% from its price of ₩992 on 26 June 2020. The South Korean market is up 11% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 23% over the same period. Tillkännagivande • Sep 22
GL Pharm Tech Corp. announced that it expects to receive KRW 1.000000232 billion in funding from Kyperion Co., Ltd. GL Pharm Tech Corp. (KOSDAQ:A204840) announced a private placement of 1,152,074 common of par value KRW 100 per share, at an issue price of KRW 868 per share for gross proceeds of KRW 1,000,000,232 on September 21, 2020. The transaction will include participation from Kyperion Co., Ltd for all the shares in the transaction. The company will raise the funding through third party allocation method. The total number of shares issued before the transaction is 46,058,145 shares. All securities to be issued in the transaction will be subject to a lock-up period of one year. The transaction was approved by the bard of directors of the company, and is expected to close on September 29, 2020. The securities are issued at 10% per discount. 